MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the beneficial healing effects of MiMedx dehydrated human amnion/chorion membrane allografts in burn management are demonstrated in the February 2017 supplement edition of the peer-reviewed Annals of Plastic Surgery.
The peer-reviewed Annals of Plastic Surgery, Volume 78, Supplement 1, February 2017, can be found on line at http://journals.lww.com/annalsplasticsurgery/toc/2017/02001, and the hard copy will be available on February 23, 2017.
The Company-sponsored supplement entitled "The Evolution of Burn Injury Management: Using Dehydrated Human Amnion/Chorion Membrane Allografts in Clinical Practice" includes an introduction by Paul M. Glat, MD, referencing MiMedx EpiFix®, EpiBurn® and AmnioFix®. Dr. Glat states that the ability of EpiFix, EpiBurn and AmnioFix to aid in the regeneration and healing of many different tissue types has become apparent in the medical community; that scientific investigation has shown these dehydrated human amnion/chorion membrane allografts contain growth factors and cytokines, including immunomodulatory chemokines, immunomodulatory cytokines, and tissue growth promoting factors; and that angiogenic growth factors retaining biologic activity are also present and studies have shown the potential of these matrices to attract stem cells to the area of the wound.
Highlights of the Peer-Reviewed Articles:
The highlights of the peer-reviewed articles published in the Annals of Plastic Surgery supplement are as follows:
- History and Advancement of Burn Treatments
Authors: Hai-Fei Liu, MD, PhD; Feng Zhang, MD, PhD; and William C. Lineaweaver, MD.
Abstract: "This review presents a historical outline of burn dressings, infection control, fluid resuscitation, burn surgery, skin grafting and substitutes and amniotic membrane; their current status; and prospects for the future of burn care."
- Contemporary Methods Allowing for Safe and Convenient Use of Amniotic Membrane as a Biologic Wound Dressing for Burns
Authors: David N. Herndon, MD, FACS; and Ludwik K. Branski, MD, MMS.
Abstract: "Partial-thickness burns involve damage to the upper layer of skin, which leaves nerve endings exposed, and therefore represent the most painful of several categories of thermal injuries. Historically, partial-thickness burns were treated conservatively by debriding the blisters, by daily tubbing and washing, and the application of new bandages with topical medications. Human amniotic membrane has been used for centuries as a biological wound dressing. In the past 20 years, there has been an increasing body of literature addressing the use of amniotic tissue in chronic wounds and burns. In this review, we present an overview of the use of amniotic membrane in the treatment of burns including processing methods and early clinical use. We believe that amniotic membranes have great potential in improving burn wound care in the future. Standardized processing methods and terminal sterilization ensure safety and allow the material to be available for use by health care providers around the world in clinical trials and for patient care."
- The Use of Dehydrated Human Amnion/Chorion Membranes in the Treatment of Burns and Complex Wounds
Author: Mayer Tenenhaus, MD, FACS.
Abstract: "Historically, biologic materials found in nature have been used for a wide variety of medicinal purposes, although their widespread use may be limited due to challenges in obtaining and properly preparing the material for safe clinical use. Amniotic membrane has long been recognized to possess unique properties favorable for healing. Dehydrated human amnion/chorion membrane allografts are commercially available for use in multiple sizes and configurations applicable for a variety of clinical settings and presentations. The purpose of this article is to review the therapeutic properties of amniotic membrane."
- Current Techniques for Burn Reconstruction: Using Dehydrated Human Amnion/Chorion Membrane Allografts as an Adjunctive Treatment Along the Reconstruction Ladder
Authors: Paul M. Glat, MD, FACS; and Thomas Davenport, MD
Abstract: "The reconstructive ladder is a term coined by reconstructive plastic surgeons to describe levels of increasingly complex management of wounds. The first rung of the ladder is allowing the wound to heal by secondary intention, advancing up the ladder to direct tissue closure, with skin grafting and tissue transfer (flaps) comprising the higher rungs. Skin grafting and tissue transfer (flaps) at the middle and higher rungs of the ladder are often necessary for the treatment of complex burn injuries. Our purpose is to describe how dehydrated human amnion/chorion membrane allografts may be used as an adjunctive treatment."
- Clinical Experience: Using Dehydrated Human Amnion/Chorion Membrane Allografts for Acute and Reconstructive Burn Care
Authors: Debra Ann Reilly, MD, FACS; Sean Hickey, MD; Paul M. Glat, MD, FACS; William, C. Lineaweaver, MD; and Jeremy Goverman, MD.
Abstract: "Amniotic membrane is immunologically privileged and is a reservoir of growth factors and cytokines known to modulate inflammation and enhance the healing process, while also possessing antimicrobial, antifibrosis, and antiscarring properties. These properties establish a strong argument for using amniotic membrane derived products as a treatment for burns. The purpose of this article is to describe the use of commercially available dehydrated human amnion/chorion membrane allografts in patients with partial-thickness and full-thickness burns."
Parker H. Petit, Chairman and CEO, stated, "The body of evidence demonstrating the clinical and cost effectiveness of our dHACM allografts and the body of research confirming the scientific foundation and properties of our dHACM allografts is rapidly expanding. The Company's proprietary and patented PURION® Process and strict processing standards and validations that we have developed enable our dHACM allografts to deliver superb clinical outcomes for healing, modulating inflammation and reducing scar tissue formation. We are gratified that so many renowned physicians in the burn management and reconstructive surgery specialties of the industry have such high esteem for the effectiveness of our products."
"This sponsored supplement with peer-reviewed articles authored by numerous prominent physicians is a wonderful complement to our compendium of peer-reviewed published studies. Our compendium has now grown to more than 30 peer-reviewed study articles, including four Randomized Control Trials (RCTs), scientific studies and significant case studies. We are very excited about the opportunities that are available in the burn management and plastic and reconstructive surgery sector of the market," added Bill Taylor, President and COO.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the Company's processing standards and validations enable its dHACM allografts to deliver superb clinical outcomes, and the opportunities available in the burn management and plastic and reconstructive surgery market sector. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company's allografts may not continue to deliver superb clinical outcomes or other products may deliver better outcomes, the esteem for the effectiveness of the Company's products by physicians in the burn management and reconstructive surgery specialties may diminish, the opportunities in the burn management and plastic and reconstructive surgery market sector may not materialize or be as expected, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2015, and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/benefits-of-mimedx-dhacm-allograft-chronicled-in-multiple-articles-in-february-2017-supplement-edition-of-annals-of-plastic-surgery-300403417.html
SOURCE MiMedx Group, Inc.
Press - Michael Senken, (770) 651-9100 | Investor - COCKRELL GROUP, Rich Cockrell, 877-889-1972, email@example.com, cockrellgroup.com